HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension
نویسندگان
چکیده
منابع مشابه
Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension.
References 1. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional my-eloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach f...
متن کاملErythrocytosis: the HIF pathway in control.
Organisms living under aerobic conditions need oxygen for the metabolic conversion of nutrition into energy. With the appearance of increasingly complex animals, a specialized transport system (erythrocytes) arose during evolution to provide oxygen to virtually every single cell in the body. Moreover, in case of low environmental partial pressure of oxygen, the number of erythrocytes automatica...
متن کاملThalassemia Associated Pulmonary Hypertension
Cardiac disease is the main cause of death in both forms of thalassemia; thalassemia major (TM) and thalassemia intermedia (TI). Pulmonary hypertension (PH) is one of the cardiopulmonary morbidities with high mortality that, if not treated, may trigger right-sided heart failure and premature death. PH is defined as a mean pulmonary artery pressure of ≥25 mmHg at rest or ≥30 mmHg during exercise...
متن کاملPyk2 aggravates hypoxia-induced pulmonary hypertension by activating HIF-1α.
Pulmonary arterial hypertension (PAH) is a refractory disease characterized by uncontrolled vascular remodeling and elevated pulmonary arterial pressure. Although synthetic inhibitors of some tyrosine kinases have been used to treat PAH, their therapeutic efficacies and safeties remain controversial. Thus, the establishment of novel therapeutic targets based on the molecular pathogenesis underl...
متن کاملAutosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation.
reaction (PCR) methods as previously described in detail.1,2 Forty-six (1.8%) cases showed an ambiguous result and were not considered for further analysis. Of the remaining 2498 cases, 904 (36.2%) were BCR-ABL (599 24% minor breakpoint region [m-bcr] and 282 11.3% major breakpoint region [M-bcr], 15 0.6% both, M-bcr and m-bcr, and 8 atypical transcripts), and 1594 were BCR-ABL . Atypical trans...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2021
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.2020010323